Evotec’s (EVO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evotec (NASDAQ:EVO) in a report published on Wednesday,Benzinga reports. The firm currently has a $4.00 price target on the stock.

EVO has been the topic of a number of other reports. Weiss Ratings cut Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research report on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

Evotec Stock Performance

EVO stock opened at $1.38 on Wednesday. Evotec has a twelve month low of $1.33 and a twelve month high of $4.27. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average of $1.74 and a 200 day moving average of $2.35.

Hedge Funds Weigh In On Evotec

A number of hedge funds have recently bought and sold shares of EVO. SmartHarvest Portfolios LLC bought a new position in Evotec during the 1st quarter valued at about $44,000. Apollon Wealth Management LLC purchased a new stake in shares of Evotec during the 1st quarter valued at about $28,000. WCM Investment Management LLC grew its stake in shares of Evotec by 12.1% in the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after acquiring an additional 67,917 shares during the period. Finally, Optiver Holding B.V. grew its stake in shares of Evotec by 598.4% in the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after acquiring an additional 242,973 shares during the period. Hedge funds and other institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.

Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services.